P129 Elevated NTproBNP in patients with Crohn's disease
J.-F. Colombel, Gail M. Comer(Pfizer (United States)), Gert Van Assche(KU Leuven), Sunday Rivers(Pfizer (United States)), Bo Jin, James Potts, Kenneth J. Gorelick, George Cooke, Fabio Cataldi(Pfizer (United States))
Cited by 0
Related Papers
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations
|Journal of Crohn s and Colitis|2009|897
Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy
|JAMA|2019|370